Home › Non-Small Cell Lung Cancer › Indiana › Indianapolis
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Indianapolis, IN
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Indianapolis. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Nagre-recruitPhase 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Nagre-recruitPhase 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · 13 mi ang layo
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Nagre-recruitPhase 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Nagre-recruitPhase 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Nagre-recruitPhase 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Nagre-recruitPhase 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- at 1 pa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Nagre-recruitPhase 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Nagre-recruitPhase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
Nagre-recruitPhase 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
Nagre-recruitPhase 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Nagre-recruitPhase 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Nagre-recruit
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Nagre-recruit
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Nagre-recruitPhase 1/2
- Community Health Network, Inc., Indianapolis
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Indianapolis
- Kanser (lahat ng uri)24 pag-aaral
- Pagkabigo ng Puso23 pag-aaral
- Obesity20 pag-aaral
- Kanser sa Suso20 pag-aaral
- Metastatic Cancer19 pag-aaral
- Colorectal Cancer18 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Sakit sa Puso at Ugat ng Dugo17 pag-aaral
- Kanser sa Baga16 pag-aaral
- Type 1 Diabetes14 pag-aaral
- Kanser ng Endometrium14 pag-aaral
- Sakit ni Alzheimer14 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.